Eloralintide: What the Clinical Research Shows

Eloralintide (also known as LY3841136) is an investigational, long-acting amylin receptor agonist developed by Eli Lilly. Published human evidence includes a Phase 1 study and a 48-week Phase 2 trial. It remains under clinical investigation; those studies do not establish regulatory approval or long-term outcomes.

This guide focuses on the compound’s own evidence and current clinical development. For a broader overview of amylin combinations, see GLP-1 + amylin combination research.

Amylin receptors are formed from the calcitonin receptor and receptor activity-modifying proteins. Eloralintide is described as selective because laboratory assays found stronger activity at amylin receptor targets than at the calcitonin receptor. “Selective” does not mean that activity at the calcitonin receptor is absent.

Cagrilintide is commonly described as a dual amylin and calcitonin receptor agonist. These pharmacological descriptions distinguish how the compounds behave in assays; they do not establish which would be more effective or better tolerated in people. The compounds have not been compared head to head in a clinical trial cited here.

A randomised, placebo-controlled Phase 1 study enrolled 100 adults with overweight or obesity and followed participants for 12 weeks. It examined safety, tolerability, pharmacokinetics, and pharmacodynamic measures across multiple study groups.

The study provides early human evidence, but its size and duration limit what it can establish about longer-term outcomes. It was not designed to answer whether eloralintide prevents obesity-related complications or how it compares with established treatments.

The multicentre, double-blind, randomised, placebo-controlled Phase 2 trial enrolled 263 adults with obesity, or overweight plus a weight-related comorbidity. Participants did not have type 2 diabetes. The study compared several eloralintide treatment groups, including fixed-dose and dose-escalation arms, with placebo over 48 weeks.

Mean percent change in body weight from baseline ranged from −9% to −20% across the fixed-dose groups and from −16% to −20% across the dose-escalation groups, compared with −0.4% for placebo. These are results from the trial’s efficacy estimand, which estimates outcomes had participants remained on assigned treatment under the analysis assumptions. They are trial findings, not a forecast for an individual or a comparison with another medicine.

Nausea and fatigue were among the most frequently reported adverse events in the Phase 2 study. Nausea varied from 11% to 64% across eloralintide groups, compared with 14% for placebo; fatigue varied from 0% to 46%, compared with 12% for placebo. The variation between trial arms is one reason not to summarise tolerability with a single headline claim.

The Phase 2 findings come from one 48-week study of adults without type 2 diabetes. The trial does not establish long-term safety, outcomes in other populations, or superiority to another treatment. Comparisons with separate cagrilintide, CagriSema, or GLP-1 trials cannot answer those questions because their participants and study designs differ.

As of September 2026, Lilly reports that Phase 3 studies of eloralintide are ongoing. On 30 September 2026, the company also announced Phase 2b results for EloraTZP, a separate investigational combination of eloralintide and tirzepatide, from a 48-week study in 367 adults with overweight or obesity and type 2 diabetes.

Lilly reported up to 23.3% mean body-weight change for a combination group versus 14.8% for tirzepatide alone. These results were announced by the sponsor alongside a conference presentation; they are not a peer-reviewed journal publication. The primary comparison was combination treatment versus placebo, while other comparisons were secondary. The combination findings should not be attributed to eloralintide monotherapy.

Eloralintide is an investigational compound, and clinical-trial results are not a protocol for laboratory or personal use. Hati Peptides plans to stock eloralintide as a research reference material; check the product catalogue for current availability and batch documentation when the listing is live.

Research reference materials are not licensed medicines and are not for human or animal use.